Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biovitrum Creates Rare-Disease Focused Spec Pharma with Swedish Orphan Buy

This article was originally published in The Pink Sheet Daily

Executive Summary

The Swedish biotech pays roughly $500 million for a company with a revenue stream from commercial products as part of its transition into a spec pharma.
Advertisement

Related Content

Specialty Pharma In Europe: Is Long-Term Independence Still An Option?
Specialty Pharma In Europe: Is Long-Term Independence Still An Option?
European Spec Pharma Testing New Niches: Emerging Markets, Novel Products
European Spec Pharma Testing New Niches: Emerging Markets, Novel Products
Two Partnerships Tackle Status Quo In Hemophilia, One With Long-Acting Coagulation Factors, Other With Increased Access To Therapy
Two Partnerships Tackle Status Quo In Hemophilia, One With Long-Acting Coagulation Factors, Other With Increased Access To Therapy

Topics

Advertisement
UsernamePublicRestriction

Register

PS068836

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel